If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...

Regeneron Pharmaceuticals (REGN) is gearing up for an earnings announcement that could pivot its stock's current trajectory.